Allergan’s Forest to face jury in antitrust suit over Alzheimer drug

15-06-2021

Muireann Bolger

Allergan’s Forest to face jury in antitrust suit over Alzheimer drug

rafapress / Shutterstock.com

Allergan subsidiary Forest Laboratories will have to argue its case before a jury over claims that it used pay-for-delay deals to keep generic copies of blockbuster Alzheimer drug, Namenda (memantine), from the marketplace.


Allergan, Forest, Namenda, Merz, patent, antitrust, pay-for-delay deals, big pharma

LSIPR